Journal article
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells
Abstract
Novel agents such as the Bcl-2 inhibitor venetoclax (ABT-199) are changing treatment paradigms for chronic lymphocytic leukemia (CLL) but important problems remain. Although some patients exhibit deep and durable responses to venetoclax as a single agent, other patients harbor subpopulations of resistant leukemia cells that mediate disease recurrence. One hypothesis for the origin of resistance to venetoclax is by kinase-mediated survival …
Authors
Oppermann S; Ylanko J; Shi Y; Hariharan S; Oakes CC; Brauer PM; Zúñiga-Pflücker JC; Leber B; Spaner DE; Andrews DW
Journal
Blood, Vol. 128, No. 7, pp. 934–947
Publisher
American Society of Hematology
Publication Date
August 18, 2016
DOI
10.1182/blood-2015-12-687814
ISSN
0006-4971
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdenineBridged Bicyclo Compounds, HeterocyclicCellular MicroenvironmentDose-Response Relationship, DrugDrug Evaluation, PreclinicalDrug Resistance, NeoplasmHumansImaging, Three-DimensionalIndolesLeukemia, Lymphocytic, Chronic, B-CellMutationPiperidinesProtein Kinase InhibitorsPurinesPyrazolesPyrimidinesPyrrolesQuinazolinonesReproducibility of ResultsSignal TransductionStromal CellsSulfonamidesSunitinibUp-Regulationbcl-X Protein